MAGEA1 and hepatocellular carcinoma: Another completed phase II clinical trial (JPRN-UMIN000021545) evaluated the clinical results of a mature-DC vaccine co-pulsed with AFP, MAGE-1, and GPC-3 proteins cand given in combination with surgical resection in treating patients with unresectable primary HCC.